FDA approves SOMA 250 mg
The Food and Drug Administration (FDA) has approved SOMA (carisoprodol) 250 mg as a new recommended dose. SOMA is a skeletal muscle relaxant, indicated for treatment of painful musculoskeletal conditions such as backache.SOMA is a well-established brand in the US and the substance carisoprodol, generates around 10 million prescriptions per year. SOMA 250 mg is now the only available low-dose treatment of carisoprodol that can offer similar efficacy as SOMA 350 mg but with a more favourable tolerability profile. SOMA 250mg is granted a minimum 3 year exclusivity period in the US. The